Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer"

被引：3

作者：

Agrawal A. ^{[1
]}

Robertson J.F.R. ^{[1
]}

Cheung K.L. ^{[1
]}

机构：

[1] Professorial Unit of Surgery, City Hospital, University of Nottingham

来源：

World Journal of Surgical Oncology | / 4卷 / 1期

关键词：

Tamoxifen; Endocrine Therapy; Fulvestrant; Goserelin; Metastatic Breast Cancer Patient;

D O I：

10.1186/1477-7819-4-40

中图分类号：

学科分类号：

摘要：

Background: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. Methods: Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data was exported to SPSS™ software for statistical analysis. Results: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively. The remaining 64(28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months respectively. Conclusion: The chance of further endocrine response continues to decrease with each line of therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further endocrine response, with long duration, can be seen in a significant proportion of patients who have developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy should not be excluded under these circumstances. © 2006 Agrawal et al; licensee BioMed Central Ltd.

引用

共 19 条

[1]

Bonadonna G., Valagussa P., Chemotherapy of breast cancer: Current views and results, Int J Radiat Oncol Biol Phys, 9, 3, pp. 279-297, (1983)

[2]

Agrawal A., Mustafa T., Gutteridge E., Robertson J.F.R., Cheung K.L., Response to further endocrine therapies following de novo or acquired resistance to first line endocrine therapy for advanced breast cancer, Eur J Cancer, 37, SUPPL. 5, (2005)

[3]

Hayward J.L., Carbone P.P., Heuson J.C., Assessment of response to therapy in advanced breast cancer, Cancer, 39, pp. 1289-1293, (1977)

[4]

Assessment of response to treatment in advanced breast cancer, Lancet, 2, pp. 38-39, (1974)

[5]

Robertson J.F.R., Willsher P.C., Cheung K.L., Blamey R.W., The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer, European Journal of Cancer, 33, 11, pp. 1774-1779, (1997)

[6]

Horwitz K.B., Mechanisms of hormone resistance in breast cancer, Breast Cancer Res Treat, 26, 2, pp. 119-130, (1993)

[7]

Dowsett M., Endocrine resistance in advanced breast cancer, Acta Oncol, 35, SUPPL. 5, pp. 91-95, (1996)

[8]

Hardin C., Pommier R., Lefleur B., Jackson T., Toth-Fejel S., Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment, Am J Surg, 188, 4, pp. 426-428, (2004)

[9]

Robertson J.F., Bates K., Pearson D., Blamey R.W., Nicholson R.I., Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer, Br J Cancer, 65, 5, pp. 727-730, (1992)

[10]

Williams M.R., Todd J.H., Ellis I.O., Dowle C.S., Haybittle J.L., Elston C.W., Nicholson R.I., Griffiths K., Blamey R.W., Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases, Br J Cancer, 55, 1, pp. 67-73, (1987)

← 1 2 →